Robe Mesa feasibility study funded
CZR approved a $5 million Definitive Feasibility Study budget for Robe Mesa in June 2021.
A financial review of CZR's exploration and development period, using Australian-dollar statutory statements and the actual June year ends. The FY2024 proposed disposal and FY2025 transaction reversal materially affect comparisons.
Reading the tables: 0 (nil) is a supported zero. Other text distinguishes an amount included in another line, a non-applicable item, a separately unavailable component and an unresolved value. These are not interchangeable. Period-specific detail is labelled; complete year-by-year detail remains available.
Statutory loss, including reversal of the prior tax benefit.
At 30 June 2025; excludes the later sale settlement.
At 30 June 2025.
CZR was a mineral explorer and developer during the five reporting years. Robe Mesa study and transaction activity dominated the period; statutory profit in FY2024 reflected a tax benefit associated with the proposed disposal, which reversed in FY2025 after that transaction ended.
All five annual statements are for years ended 30 June and are presented in Australian dollars. The 1:17 share consolidation completed in December 2022 limits direct comparison of per-share figures and share counts across that date. The Robe Mesa tenement sale settled after the FY2025 balance date; its settlement proceeds are outside FY2025 cash flow and financial position.
CZR approved a $5 million Definitive Feasibility Study budget for Robe Mesa in June 2021.
A June 2022 Robe Mesa resource update reported 37.5 Mt at 56% Fe, using a 55% Fe cut-off.
A 1:17 share consolidation took effect in December 2022; the rights issue and shortfall placement supported the development program.
The proposed Robe Mesa transaction brought a $1 million exclusivity fee and a $14.89 million income tax benefit into the year's accounts.
After termination of the Miracle Iron transaction, the prior tax benefit reversed. The replacement RRJV sale settled on 9 September 2025, after year end.
The FY2024 result includes a tax benefit tied to the proposed Robe Mesa disposal. Its reversal in FY2025 explains much of the subsequent statutory loss; the pre-tax line shows the operating and transaction cost burden separately.
Exploration expense eased after completion of the Robe Mesa DFS. FY2025 also includes corporate transaction costs associated with the Fenix and RRJV transactions.
AUD
AI-generated presentation · values from Consolidated statutory result; no missing values plotted as zero.
AUD
AI-generated presentation · values from Named expense components; no missing values plotted as zero.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Other income | 13,051 | 899 | 105,860 | 1,040,761 | 674,935 |
| (Loss) before income tax | (3,980,087) | (5,804,791) | (7,107,858) | (4,395,119) | (3,917,813) |
| Income tax benefit / (expense) | 0 (nil) | 0 (nil) | 0 (nil) | 14,889,690 | (14,889,690) |
| Net profit / (loss) after tax | (3,980,087) | (5,804,791) | (7,107,858) | 10,494,571 | (18,807,503) |
| Basic (loss) / profit per sharecents per share | (0.14) | (0.17) | (3.21) | 4.45 | (7.95) |
| Diluted (loss) / profit per sharecents per share | (0.14) | (0.17) | (3.21) | 4.33 | Not applicable (reported) |
AUD except per-share rows, which are cents per share. Parentheses denote losses or expenses.
FY2021-FY2022 per-share figures precede the December 2022 1:17 share consolidation; they are not adjusted into a common share base.
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Exploration costs (expensed) | (2,948,600) | (4,679,661) | (5,491,181) | (2,628,584) | (1,913,024) |
| Share based payment expense | (75,026) | (122,840) | (542,594) | (1,553,362) | (108,723) |
| Compliance and professional fees | (458,125) | (504,929) | (502,826) | (557,312) | (477,318) |
| Corporate transactions costs | Not separately presented | Not separately presented | Not separately presented | Not separately presented | (1,285,440) |
| Directors' fees | (259,656) | (175,405) | (139,156) | (338,488) | (144,506) |
| Occupancy expenses | (35,386) | (63,824) | (77,070) | (80,035) | (83,013) |
| Administration expenses | (137,977) | (244,936) | (154,811) | (239,051) | (280,160) |
| Depreciation and amortisation | (11,148) | (14,095) | (20,111) | (17,618) | (10,152) |
| Share of loss of joint ventures (equity method) | Not separately presented | Not separately presented | Not separately presented | (11,215) | (95,741) |
| Capitalised exploration and evaluation expenditure impaired | 0 (nil) | 0 (nil) | (285,249) | 0 (nil) | Not separately presented |
| Finance costs / net finance charge (issuer line; basis changes) | (32,105) | 0 (nil) | 0 (nil) | (10,000) | (194,671) |
Reported expense signs retained. A not separately presented line is not a zero amount.
FY2021–FY2023 source statements use a net finance charge/(benefit) line; FY2024–FY2025 present finance costs. The basis change is explicit, so gross costs are not inferred for the earlier nil years. FY2022 exploration impairment uses its own asset-note fact, not the finance-line pointer.
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
The held-for-sale classification and tax balances reshape the FY2024 and FY2025 asset and liability totals. The FY2025 current borrowings and liabilities linked to held-for-sale assets are separate obligations; both are shown below.
AUD
AI-generated presentation · values from Consolidated statement of financial position; no missing values plotted as zero.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 5,117,356 | 3,120,947 | 2,169,445 | 588,832 | 187,906 |
| Trade and other receivables | 135,598 | 97,313 | 164,034 | 84,185 | 99,895 |
| Assets of disposal group held for sale | Not applicable | Not applicable | Not applicable | 9,493,707 | 9,247,201 |
| Total current assets | 5,252,954 | 3,218,260 | 2,333,479 | 10,166,724 | 9,535,002 |
| Investments accounted for using the equity method | Not separately presented | Not separately presented | Not separately presented | Not separately presented | 23,544 |
| Property, plant and equipment | 36,167 | 58,292 | 37,461 | 21,364 | 4,332 |
| Exploration assets | 13,479,037 | 13,499,466 | 14,061,375 | 4,632,475 | 4,821,054 |
| Deferred tax asset | Not separately presented | Not separately presented | Not separately presented | 27,822,157 | 0 (nil) |
| Total non-current assets | 13,515,204 | 13,557,758 | 14,098,836 | 32,475,996 | 4,848,930 |
| Total assets | 18,768,158 | 16,776,018 | 16,432,315 | 42,642,720 | 14,383,932 |
| Trade and other payables | 324,204 | 752,593 | 855,994 | 1,072,115 | 1,066,625 |
| Current borrowings | 0 (nil) | Not separately presented | Not separately presented | Not separately presented | 1,500,000 |
| Current provisions | 21,047 | 22,574 | 49,147 | 64,159 | 80,432 |
| Liabilities directly associated with held-for-sale assets | Not applicable | Not applicable | Not applicable | 991,670 | 2,850,000 |
| Current income tax payable | Not separately presented | Not separately presented | Not separately presented | 12,548,282 | 0 (nil) |
| Total current liabilities | 345,251 | 775,167 | 905,141 | 14,676,226 | 5,497,057 |
| Working capital | 4,907,703 | 2,443,093 | 1,428,338 | (4,509,502) | 4,037,945 |
| Non-current provisions | 948 | 587 | 4,430 | 11,632 | 14,961 |
| Deferred tax liability | Not separately presented | Not separately presented | Not separately presented | 384,185 | 0 (nil) |
| Total non-current liabilities | 948 | 587 | 4,430 | 395,817 | 14,961 |
| Total liabilities | 346,199 | 775,754 | 909,571 | 15,072,043 | 5,512,018 |
| Net assets | 18,421,959 | 16,000,264 | 15,522,744 | 27,570,677 | 8,871,914 |
| Contributed equity | 42,557,388 | 45,817,644 | 51,905,388 | 51,905,388 | 51,905,405 |
| Reserves | 3,821,842 | 3,944,682 | 4,487,276 | 6,040,638 | 6,149,361 |
| Accumulated losses | (27,957,271) | (33,762,062) | (40,869,920) | (30,375,349) | (49,182,852) |
| Total equity | 18,421,959 | 16,000,264 | 15,522,744 | 27,570,677 | 8,871,914 |
AUD at 30 June each year. Blank line items in an earlier statement are shown as not separately presented, rather than nil.
The FY2025 held-for-sale liability is AUD 2,850,000; its FY2024 comparative is AUD 991,670. Deferred tax asset and liability are separate rows.
The FY2025 deferred-tax asset, income-tax payable and deferred-tax liability dashes are displayed as nil only after same-statement section totals reconcile to the other named components; calculation locators are retained in evidence.
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
Operating cash use stayed material throughout the period. Cash raised from ordinary shares funded FY2021-FY2023 deficits; borrowing proceeds became the main financing inflow in FY2024-FY2025. Robe Mesa exclusivity receipts and the Fenix break fee are shown in investing cash flow as classified in the annual statements.
AUD
AI-generated presentation · values from Cash-flow bridge; no missing values plotted as zero.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Opening cash and cash equivalents | 4,646,115 | 5,117,356 | 3,120,947 | 2,169,445 | 588,832 |
| Net operating cash flow | (3,875,314) | (5,163,879) | (6,225,422) | (3,461,189) | (3,679,273) |
| Net investing cash flow | (43,145) | (56,649) | (155,000) | 888,906 | (80,000) |
| Net financing cash flow | 4,389,700 | 3,224,119 | 5,428,920 | 991,670 | 3,358,347 |
| Net change in cash and cash equivalents | 471,241 | (1,996,409) | (951,502) | (1,580,613) | (400,926) |
| Closing cash and cash equivalents | 5,117,356 | 3,120,947 | 2,169,445 | 588,832 | 187,906 |
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash paid to suppliers and employees | (939,478) | (969,433) | (810,364) | (864,402) | (1,504,222) |
| Interest received | 513 | 899 | 66,545 | 39,969 | 21,246 |
| Other income received | 12,538 | 0 (nil) | 39,315 | 792 | 3,689 |
| Payments for exploration expenditure | (2,948,887) | (4,195,345) | (5,520,918) | (2,637,548) | (2,159,628) |
| Interest paid | Not separately presented | Not separately presented | Not separately presented | Not separately presented | (40,358) |
AUD; interest paid is separate from interest received. No earlier-year interest-paid line is inferred from a later-year amount.
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Payments for tenement acquisitions | Not separately presented | Not separately presented | (155,000) | (58,858) | 0 (nil) |
| Stamp duty on tenement acquisition | (35,115) | (20,429) | Not separately presented | Not separately presented | Not separately presented |
| Payments for investments | Not separately presented | Not separately presented | Not separately presented | (50,500) | (80,000) |
| Payments for property, plant and equipment | (8,030) | (36,220) | 0 (nil) | (1,986) | 0 (nil) |
| Proceeds from sale of property, plant and equipment | Not separately presented | Not separately presented | Not separately presented | 250 | 0 (nil) |
| Robe Mesa exclusivity fees received | Not applicable | Not applicable | Not applicable | 1,000,000 | 650,000 |
| Fenix transaction break fee paid | Not applicable | Not applicable | Not applicable | Not applicable | (650,000) |
AUD; PP&E cash payments are flows, not PP&E carrying values. The exclusivity receipt appears on a wrapped source row.
FY2021–FY2022 stamp-duty payments are narrower than later tenement-acquisition payments. They are retained as distinct rows; no combined comparable amount is imposed across the wording change.
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Proceeds from issue of ordinary shares | 4,702,000 | 3,283,000 | 5,581,682 | 0 (nil) | 17 |
| Payment of share issue costs | (312,300) | (58,881) | (152,762) | 0 (nil) | 0 (nil) |
| Proceeds from borrowings | 0 (nil) | Not separately presented | Not separately presented | 991,670 | 6,626,000 |
| Repayment of borrowings | Not separately presented | Not separately presented | Not separately presented | Not separately presented | (3,267,670) |
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
No dividend was paid or declared in the five annual-report periods. The ordinary-share denominator changed substantially with the FY2023 consolidation, so EPS across that boundary needs care.
AUD
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Dividend | None paid, declared or recommended | None paid, declared or recommended | None paid, declared or recommended | None paid, declared or recommended | None paid, declared or recommended |
Nil is supported by issuer dividend statements; it does not imply all capital-return mechanisms were absent.
No-dividend statements are qualitative decisions covering paid, declared and recommended status; no numeric return amount is asserted.
Source: CZR Resources annual reports; current-year consolidated statement columns, unless noted.
Prepared from the existing annual extraction datasets, supplemented only by selected same-company annual-report tables and saved row interpretations. No new raw-document extraction or web financial research was used for this test.
The source references in this report identify the public disclosures used and should be read with the associated section, table and reporting-period qualifications. This report paraphrases, organises and compares those disclosures for descriptive and educational purposes rather than reproducing source text.
Copyright and other rights in linked reports, company names, logos and third-party materials remain with their respective owners. MII Research does not claim affiliation with or endorsement by the company covered in this report, the ASX or cited organisations.
This report uses AI actively and extensively for evidence extraction, comparison, organisation, calculation checks, drafting, translation planning and presentation. Material claims received reasonable editorial review against cited public sources; this was not an audit, assurance engagement or independent verification. Limitations in public sources, AI systems and review may leave errors, omissions, inconsistencies or translation, classification and interpretation errors.
Any AI-generated visual accompanying this report must carry an adjacent, visible AI-generated label or caption. Such visuals are illustrative rather than source evidence and do not replace the cited annual-report text, table or section source.
This record is for general descriptive and educational information only. It is not financial-product, investment, legal, tax, technical or other professional advice; it is not a securities recommendation, valuation, target price, offer, solicitation or invitation to buy, sell or hold.
It does not consider any reader’s objectives, financial situation, needs, knowledge, experience or risk tolerance. Independently verify material information against the primary disclosures, obtain appropriate independent professional advice and do not use this record as the sole or primary basis for any decision.
Public sources are used in good faith, but no representation or warranty is made as to accuracy, completeness, reliability, currency or fitness for a particular purpose. To the maximum extent permitted by law, MII Research disclaims liability for direct, indirect, incidental, consequential, opportunity or investment loss arising from use of or reliance on this record; nothing excludes or limits liability that cannot lawfully be excluded or limited.
Report suspected errors to MII Research with the relevant report section and primary-source document and page reference so that the record can be reviewed and corrected where appropriate.